Literature DB >> 17594344

Vincristine-induced acute neurotoxicity versus Guillain-Barré syndrome: a diagnostic dilemma.

P González Pérez1, A Serrano-Pozo, E Franco-Macías, E Montes-Latorre, F Gómez-Aranda, T Campos.   

Abstract

We report the case of a patient with acute lymphoblastic leukaemia who, after the initiation of treatment with vincristine (VCR), developed a fulminant motor polyradiculoneuropathy resembling an axonal variant of Guillain-Barré syndrome (GBS). This report shows that differentiating between axonal GBS and VCR-induced acute neurotoxicity may be a challenge for clinicians.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17594344     DOI： 10.1111/j.1468-1331.2007.01842.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN： 1351-5101            Impact factor:   6.089


  4 in total

1.  Efficacy of vincristine administered via convection-enhanced delivery in a rodent brainstem tumor model documented by bioluminescence imaging.

Authors:  Guifa Xi; Veena Rajaram; Babara Mania-Farnell; Chandra S Mayanil; Marcelo B Soares; Tadanori Tomita; Stewart Goldman
Journal:  Childs Nerv Syst       Date:  2012-01-27       Impact factor: 1.475

2.  Guillain-Barre Syndrome in a Patient with Primary Extranodal Intestinal Non-Hodgkin's Lymphoma: Paraneoplastic, Drug Induced or Coincidental?

Authors:  Aslı Kiyat Atamer; Kerem Okutur; Erdem Tüzün; Barış Hasbal; Ari Boyaciyan; Yakup Krespi; Gökhan Demir
Journal:  Noro Psikiyatr Ars       Date:  2014-09-01       Impact factor: 1.339

3.  A case of Miller Fisher syndrome during preoperative chemotherapy for breast cancer.

Authors:  Yumiko Taki; Yoshimi Ide; Shogo Tajima; Yuko Hosokawa; Ryoichi Matsunuma; Tatsuhiro Terada; Michihiko Waki; Hiroyuki Ogura; Norihiko Shiiya
Journal:  Int J Clin Exp Med       Date:  2015-09-15

Review 4.  Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review.

Authors:  Nicolas Kerckhove; Aurore Collin; Sakahlé Condé; Carine Chaleteix; Denis Pezet; David Balayssac
Journal:  Front Pharmacol       Date:  2017-02-24       Impact factor: 5.810
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.